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•	 Joint Effects of 
Environmental Exposures 
and Familial Susceptibility 
to Lung Cancer in Chinese 
Never Smoking Men and 
Women
OPTOMETRY AND VISION SCIENCE
Copyright © 2014 American Academy of Optometry
In this study of delineating the joint effects of individual 
environmental risk factors and familial susceptibility to 
lung cancer, 345 never-smoking lung cancer cases and 
828 community referents (from two case-referent studies 
between female and male lung cancer studies) were 
recruited. The authors developed a novel environmental 
exposure index, in which subjects at high risk of lung 
cancer with respect to environmental risk factors were 
assigned a value of 1 and 0 otherwise. The identified 
factors were then summed over using weights equivalent 
to the excess odds ratio. Potential additive interactions 
between environmental exposure index and family cancer 
history on lung cancer risk were evaluated. Males with 
high environmental exposures but no family cancer history 
demonstrated an odds ratio of 6.80 versus those with low 
environmental exposure and no family cancer history. The 
ratio increased dramatically to 30.61 when family cancer 
history was also present, where a statistically significant 
synergy index between environmental exposure index and 
family history of 3.98 was detected. Among females with 
high environmental exposures and a positive family history, 
the association to lung cancer risk was weaker, with a 
synergy index of 1.21. The findings suggest that there were 
joint effects of environmental exposure index and familial 
susceptibility to lung cancer risk in the never-smoking 
population and that there was a gender difference in these 
joint effects. Further studies are required to confirm this 
interaction in the male and female population. (p. 1066)
IN THIS ISSUE
•	 Genetic Susceptibility, 
Residential Radon, and 
Lung Cancer in a Radon 
Prone Area
This study sought to investigate the association of 
residential radon exposure, GSTM1 and GSTT1 
polymorphisms, and the risk of lung cancer. Confirmed 
lung cancer cases and controls, without a previous 
neoplasm, aged >30 years, and divided into never/light 
smokers and moderate/heavy smokers, were included in 
the analysis. Of the 792 individuals analyzed, odds ratios 
(OR) of 1.38 and 1.13 were observed in cases of GSTM1 
and GSTT1 deletion, respectively. When compared with 
cases with the presence of GSTM1 and residential radon 
at < 50 Bq/m3, an OR of 1.48 was demonstrated in cases 
with higher residential radon exposure (> 148 Bq/m3) in 
the presence of GSTM1, and an OR of 2.64 in the absence 
of GSTM1. Similar results were observed in the moderate/
heavy smokers. The authors concluded that GSTM1 
and GSTT1 deletions increase the risk of lung cancer 
in subjects exposed to residential radon, pointing to the 
possible modulatory role of these genes on the effect of 
environmental exposures. Further studies are warranted to 
confirm this effect in never smokers. (p. 1073)
Photo source: NIH
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•	 Surgery for Small 
Cell Lung Cancer: A 
Retrospective Analysis of 
243 Patients from Japanese 
Lung Cancer Registry in 
2004
the registry, SCLC patients accounted for 2.1% (n = 243), 
whose surgical outcomes and clinicopathologic data were 
analyzed. An overall 5-year survival rate of 52.6% was 
observed in all 243 cases. When stratified by clinical tumor, 
node, metastasis (TNM) stage (c-stage) and pathological 
TNM stage (p-stage), the 5-year survival rates generally 
declined with higher stage. From IA to IV of c-stage and 
p-stage, the rates were 64.3% and 72.3%, to 0% and 0%, 
respectively. Age, gender, c-stage, and surgical curability 
were significant prognostic factors. The findings suggest 
that patients with early-stage SCLC, particularly stage I, 
had survival benefits from surgical resection. The authors 
suggested that c-stage II SCLC patients might also have 
good surgical outcome, and a clinical trial on surgery for 
these patients is recommended.  (p. 1140)
Takei et al. conducted a retrospective study of the prognosis and 
clinicopathologic profiles in a large number of small-cell lung cancer 
(SCLC) patients from the Japanese Joint Committee of Lung Cancer 
Registry who underwent surgery in 2004. Of the 11,663 patients from 
•	 Comprehensive 
Pathological Analyses 
in Lung Squamous 
Cell Carcinoma: Single 
Cell Invasion, Nuclear 
Diameter and Tumor 
Budding Are Independent 
Prognostic Factors for 
Worse Outcomes
analyses included tumor differentiation, subtypes, 
tumor nest size, and nuclear grade. Significantly shorter 
overall survival (OS) was observed in patients with 
single cell invasion versus without (p = 0.002 for the 
entire tumor and p = 0.001 for tumor edge), with large 
versus small nuclei (p = 0.011), and with high versus 
low grade tumor budding (p < 0.001 for maximum and 
p = 0.007 for total). Multivariate analyses demonstrated 
that single cell invasion, nuclear diameter, and tumor 
budding, but not histologic subtypes, were independent 
prognostic factors of OS. The findings, if confirmed and 
validated by independent cohorts, could have potential 
implications on the revision of the WHO classification, 
particularly histologic subtyping and grading according to 
keratinization. These findings would help stratify SCLC 
patients for adjuvant therapy. (p. 1126)
This study by Kadota et al. aimed to determine the prognostic 
values of pathological findings in lung squamous cell carcinoma. 
They reviewed 485 slides from resected stages I, II, and III lung 
squamous cell carcinomas from 1999 to 2009. The comprehensive 
RESEARCH WATCH
•	 Predictive Value of the 
International Association for 
the Study of Lung Cancer/
American Thoracic Society/
European Respiratory 
Society Classification of 
Lung Adenocarcinoma in 
Tumor Recurrence and 
Patient Survival 
which were also found to be significantly highly likely to 
develop initial extra-thoracic-only recurrence compared 
with other types (p < 0.01). The predominant micro-
papillary and solid pattern was of significant prognostic 
value for overall survival (OS; p < 0.01), probability of 
freedom from recurrence (p < 0.01), and disease-specific 
survival (p < 0.01). Solid-predominant adenocarcinoma 
significantly predicts for poor OS in patients treated 
with adjuvant chemotherapy (p = 0.04). Taken together, 
the IASLC/ATS/ERS classification system exhibits 
significant predictive value for recurrence and survival, 
which can help guide selecting patients for aggressive 
adjuvant chemoradiotherapy.
Hung JJ, Yeh YC, Jeng WJ, et al. Predictive value 
of the International Association for the Study of Lung 
Cancer/American Thoracic Society/European Respiratory 
society classification of lung adenocarcinoma in tumor 
recurrence and patient survival. J Clin Oncol 2014; 
doi:10.1200/jco.2013.50.1049.
Hung et al. sought to evaluate the use of the new International 
Association for the Study of Lung Cancer (IASLC)/American 
Thoracic Society (ATS)/European Respiratory Society (ERS) 
classification system in resected lung adenocarcinoma to predict 
tumor recurrence and patient survival. The proportion of each 
histological component in the resected tumors from 573 patients 
was determined and their association with recurrence and predictive 
value were assessed. Significantly higher recurrence was observed in 
micro-papillary and solid-predominant adenocarcinomas (p < 0.01), 
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•	 Using Multiplexed Assays 
of Oncogenic Drivers in 
Lung Cancers to Select 
Targeted Drugs
a targeted therapy for 28% of the 1007 patients. The 
median survival for patients with an oncogenic driver, 
receiving genotype-directed therapy was 3.5 years 
versus 2.4 years in those with a driver and did not 
receive genotype-directed therapy (hazard ratio 0.69; 
p = 0.006). This study demonstrated that multiplexed 
testing detected actionable oncogenic drivers in 64% of 
lung adenocarcinomas and assisted therapeutic decision-
making for patients with the tumors. Improved survival 
in patients with drivers receiving a matched targeted 
therapy warrants further randomized trials to confirm 
the finding.
Kris MG, Johnson BE, Berry LD, et al. Using 
multiplexed assays of oncogenic drivers in lung cancers 
to select targeted drugs. JAMA 2014;311:1998–2006. 
doi:10.1001/jama.2014.3741.
The Lung Cancer Mutation Consortium utilized multiplexed assays 
to test lung adenocarcinomas for 10 oncogenic drivers and to 
match therapies targeting the identified drivers. From 2009 to 2012, 
tumors from patients with metastatic lung adenocarcinomas and a 
performance status of 0–2 were tested for at least 1 gene (n = 1007) 
and for 10 genes (n = 733), at 14 different hospitals across the 
United States. For the latter, actionable oncogenic driver was 
detected in 64% of lung adenocarcinomas, which included KRAS 
(25%), sensitizing EGFR (17%), ALK rearrangements (8%), ERBB2 
(3%), and BRAF (2%). The findings enabled doctors to recommend 
•	 FGFR1/3 Tyrosine Kinase 
Fusions Define a Unique 
Molecular Subtype of 
Non-Small Cell Lung 
Cancer
FGFR1/3 fusions represent 1.3% non–small-cell lung cancer 
(NSCLC) patients and 3.5% lung squamous cell carcinoma. 
The authors aimed to determine the frequency, clinicopathologic 
characteristics, and treatment outcomes of NSCLC patients with 
or without these fusions. Molecular techniques were employed in 
detecting 14 known FGFR fusion variants in 1328 NSCLC patients, 
who were also tested for mutations in EGFR, KRAS, HER2, BRAF, 
ALK, RET, and ROS1. The analysis found BAG4-FGFR1 fusion 
(0.2%) and FGFR3-TACC3 fusion (1.1%) in all tumors examined. 
Six lung adenocarcinomas had FGFR3-TACC3 fusion, whereas 11 
lung squamous cell carcinomas had BAG4-FGFR1 or FGFR3-TACC3 
fusions. These FGFR fusions were significantly correlated 
with smokers (94.1%; p < 0.001), tumor >3 cm (88.2%; 
p < 0.001), and tend to be in poorly differentiated tumors 
(53.9%; p = 0.095). In this study, FGFR fusions were not 
associated with prognosis in NSCLC patients. Studies 
with a larger sample size of patients for a more definitive 
survival analysis are warranted. The findings identified 
a distinct subset of NSCLC patients harboring FGFR 
fusions, with high prevalence in smokers with squamous 
cell carcinoma and relatively larger tumors. Further 
studies of FGFR targeted therapy would potentially lead 
to a major therapeutic advance for this patient population.
Wang R, Wang L, Li Y, et al. FGFR1/3 tyrosine 
kinase fusions define a unique molecular subtype of 
non–small-cell lung cancer. Clin Cancer Res 2014. 
doi:10.1158/1078-0432.ccr-14–0284.
•	 Real-World Effectiveness 
of e-Cigarettes When Used 
to Aid Smoking Cessation: 
A Cross-Sectional 
Population Study
abstinence up to the time of survey, including odds 
adjusted for nicotine dependence, was analyzed. The 
findings demonstrated that continued abstinence was 
more likely to be observed in e-cigarette users versus 
those using over-the-counter NRT (odds ratio 2.23; 
adjusted odds 1.63) or those with no aid (odds ratio 
1.63; adjusted odds 1.61). Further studies are required to 
address limitations of the current study and establish if 
the apparent advantage of e-cigarettes is sustained.
Brown J, Beard E, Kotz D, Michie S, West R. Real-
world effectiveness of e-cigarettes when used to aid 
smoking cessation: a cross-sectional population study. 
Addiction, n/a-n/a 2014. doi:10.1111/add.12623.
Following two randomized controlled studies that indicated the 
role of e-cigarettes in mediating smoking cessation, Brown et al. 
conducted a cross-sectional survey to evaluate the effectiveness of 
e-cigarettes to aid smoking cessation compared with over-the-counter 
nicotine replacement therapy (NRT), and unaided quitting in 5863 
English adults, who had smoked within the past 1 year. Self-reported 
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•	 Passive Exposure to 
Electronic Cigarette 
(e-Cigarette) Use Increases 
Desire for Combustible 
and e-Cigarettes in Young 
Adult Smokers
regular cigarette following passive exposure to both 
combustible and e-cigarette cue (p < 0.05). Furthermore, 
exposure to e-cigarette cue alone increased the desire 
to smoke an e-cigarette (p < 0.01). For the first time 
in a controlled study, these data reflect the potential 
of e-cigarette exposure in triggering smoking urges in 
young adult daily smokers. If confirmed by forthcoming 
studies, these findings could impact electronic nicotine 
delivery systems regulation and policy.
King AC, Smith LJ, McNamara PJ, Matthews AK, 
Fridberg DJ. Passive exposure to electronic cigarette 
(e-cigarette) use increases desire for combustible and 
e-cigarettes in young adult smokers. Tobacco Control 
2014. doi:10.1136/tobaccocontrol-2014–051563.
Because passive exposure to combustible cigarette use could 
increase smoking urge, this study aimed to determine whether 
e-cigarettes and other electronic nicotine delivery systems would 
have the same impact. Subjective ratings for smoking desire and 
urge among 60 young adult daily smokers (aged 18–35 years) 
were measured before and after exposure to a control cue and 
subsequently the active cue (combustible or e-cigarette). The 
findings revealed significantly higher desire and urge to smoke a 
NEWS IN BRIEF
•	 ASCO Annual Meeting 
2014: Clinical Activity 
of the Mutant-Selective 
EGFR Inhibitor AZD9291 
in Patients with EGFR 
Inhibitor–Resistant Non-
Small Cell Lung Cancer 
(NSCLC)
AZD9291 is a third generation EGFR-TKI, which shows preclinical 
efficacy in both EGFR-TKI sensitizing and resistant T790M 
mutations. At the 50th American Society of Clinical Oncology annual 
meeting, Jänne et al. reported their findings from a phase I study of 
AZD9291 in patients with EGFR mutant non–small-cell lung cancer 
(NSCLC). Patients (n = 199) with advanced NSCLC harboring 
EGFR mutations, who had at least one prior EGFR-TKI therapy, were 
enrolled in this study for dose escalation and expansion 
cohorts. The overall response rate in all evaluable patients 
was 51% after treatment with AZD9291. Those with 
T790M mutation (n = 89) had an overall response rate of 
64% versus 23% in those without the mutation. A 96% 
of overall disease control rate was achieved in T790M-
positive patients. The responses were still ongoing in 
97% of the patients at data cut-off, with the longest 
response lasting > 8 months. There was also reduced skin 
toxicities observed with AZD9291 treatment compared 
with approved EGFR-TKIs. Taken together, the findings 
suggest that AZD9291 is effective and well-tolerated in 
EGFR mutant NSCLC patients with acquired resistance 
to EGFR-TKIs. Patients with EGFR T790M mutation 
tumors responded much better to AZD9291 than those 
without the mutation. Longer follow-up will determine 
improvement in overall survival.
•	 ASCO Annual Meeting 
2014: A Randomized, 
Multicenter, Open-
Label, Phase III Study of 
Gemcitabine-Cisplatin 
(GC) Chemotherapy Plus 
Necitumumab (IMC-11F8/
LY3012211) versus GC 
Alone in the First-Line 
Treatment of Patients with 
Stage IV Squamous Non-
Small Cell Lung Cancer 
(sq-NSCLC)
cisplatin alone. The primary endpoint was overall survival. 
Secondary endpoints were progression-free survival, 
objective response rate, and safety. Thatcher et al. reported 
the results, which demonstrated a statistically significant 
improvement in overall survival in the necitumumab 
plus chemotherapy arm (hazard ratio = 0.84; p = 0.012) 
with a median survival of 11.5 months compared with 
9.9 months in the chemotherapy-only arm. Significantly 
improved progression-free survival (hazard ratio = 0.85; 
p = 0.020) and disease control rate (82% vs. 77%; 
p = 0.043) in the necitumumab plus gemcitabine/cisplatin 
arm were also observed. Grade 3 or higher toxicities, such 
as rash and hypomagnesemia, were more frequent in the 
necitumumab plus gemcitabine/cisplatin arm. The findings 
suggest that addition of necitumumab to gemcitabine/
cisplatin offers a new first-line treatment option with 
significant survival benefits and acceptable safety profile 
for patients with squamous non–small-cell lung cancer.
Necitumumab is a human IgG1 anti-EGFR monoclonal antibody, 
targeting ligand binding, and receptor activation. In this large phase III 
SQUIRE trial, 1093 patients with stage IV squamous non–small-cell 
lung cancer who had no prior treatment were randomized to receive 
first-line necitumumab plus gemcitabine/cisplatin or gemcitabine/
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•	 ASCO Annual Meeting 
2014: REVEL–A 
Randomized, Double-
Blind, Phase III Study of 
Docetaxel (DOC) and 
Ramucirumab (RAM; 
IMC-1121B) versus DOC 
and Placebo (PL) in the 
Second-Line Treatment of 
Stage IV Non-Small Cell 
Lung Cancer (NSCLC) 
Following Disease 
Progression after One 
Prior Platinum-Based 
Therapy 
DOC + PL arm (hazard ratio [HR] = 0.857; p < 0.0235). 
The RAM + DOC arm also showed reduced risk of 
progression by 24%, extending progression-free survival 
by 1.5 months (from 3.0 to 4.5 months; HR = 0.762; 
p < 0.0001), and improved ORR from 13.6% to 22.9% 
(p < 0.001). The survival benefit was observed in both 
squamous (26% of study population) and non-squamous 
subtypes. No unexpected adverse events (AEs) were 
identified. Grade ≥ 3 AEs in the RAM + DOC versus 
DOC + PL were neutropenia (34.9% versus 28.0%), 
febrile neutropenia (15.9% versus 10.0%), fatigue 
(11.3% versus 8.1%), leukopenia (8.5% versus 7.6%), 
hypertension (5.4% versus 1.9%), and pneumonia (5.1% 
versus 5.8%). Grade 5 AEs were comparable between 
arms (5.4% in RAM + DOC versus 5.8% in DOC + PL) 
as was pulmonary hemorrhage of any grade in all patients 
(2.1% versus 1.6%) and in patients with squamous 
NSCLC (3.8% versus 2.4%). The authors concluded 
that RAM + DOC regimen, with a good safety profile, 
significantly improved overall survival, progression-free 
survival, and ORR compared with DOC + PL in the 
second-line setting for stage IV NSCLC patients who had 
received prior platinum-based therapy. Similar survival 
benefits in both squamous and non-squamous subtypes 
indicate the possibility of utilizing this regimen in treating 
all major subtypes of NSCLC.
The antiangiogenic agent ramucirumab (RAM) is a monoclonal 
antibody targeting vascular endothelial growth factor receptor-2. The 
REVEL trial aimed to investigate the efficacy and safety of RAM in 
combination with docetaxel (DOC) versus DOC plus placebo (PL) in 
1253 patients with stage IV non-squamous and squamous non–small-
cell lung cancer (NSCLC) with prior platinum-based therapy. The 
primary endpoint was overall survival, whereas the secondary 
endpoints included progression-free survival, and objective response 
rate (ORR). Pérol et al. reported the findings that showed reduced 
risk of death by 14% and improved median overall survival by 1.4 
months (from 9.1 to 10.5 months) in the RAM + DOC arm versus the 
•	 ASCO Annual Meeting 
2014: Overall Response 
Rate (ORR) as a Potential 
Surrogate for Progression-
Free Survival (PFS) 
– A meta-Analysis of 
Metastatic Non-Small Cell 
Lung Cancer (mNSCLC) 
Trials Submitted to the 
U.S. Food and Drug 
Administration (FDA)
three targeted therapy trials in molecularly defined 
population (EGFR mutant and ALK+) with high ORR. 
The analysis only included trials that were randomized, 
active-controlled, multicenter and with a sample size 
of ≥ 150. A strong correlation between ORR and 
PFS was observed (R2 = 0.89), whereas neither ORR 
nor PFS correlated well with OS (R2 = 0.12 and 0.1, 
respectively). In larger trials, the correlations between 
OS and the surrogate endpoints appeared to be modestly 
better: for PFS, R2 = 0.39 in trials with n greater than 
or equal to 500 versus 0.1 overall; for ORR, R2 = 0.50 
versus 0.12, respectively. This meta-analysis supported 
ORR as a surrogate endpoint in metastatic non–small-
cell lung cancer. No correlation was established between 
OS and PFS or ORR, which was likely because of 
confounding from high crossover, underpowered trials 
and long survival after progression in the 3 targeted 
therapy trials in molecularly enriched populations.
The meta-analysis conducted by Blumenthal et al. aimed to 
evaluate the relationship between overall response rate (ORR) 
with progression-free survival (PFS) or overall survival (OS) 
and determine a surrogate endpoint in metastatic non–small-cell 
lung cancer patients from 15 trials of 12,534 patients reviewed 
by the food and drug administration (FDA) since 2003, including 
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•	 ASCO Annual Meeting 




Small Cell Lung Cancer 
(NSCLC) – Results of the 
ASCEND-1 Trial
median duration of response of 9.7 months was observed. 
ORR was 54.6% and PFS was 6.9 months among patients 
pretreated with the ALKi crizotinib, whereas the ORR of 
66.3% was observed in the ALKi naïve patients, who were 
still under ceritinib treatment and median PFS had not 
been reached. Of note, similar findings were also observed 
in patients with brain metastases receiving ceritinib: 
ORR was 54.0% and median PFS was 6.9 months. In 
these patients, 50.0 % of the ALKi pretreated group and 
69.2% of the ALKi naïve group had tumor regression after 
ceritinib treatment. The most common adverse events were 
diarrhea, nausea, vomiting, abdominal pain, and fatigue. 
The study showed that ceritinib at 750 mg/d has rapid, 
durable, and high antitumor response in ALK+ NSCLC 
patients, regardless of ALKi pretreatment and also is 
effective in brain metastases in this study population.
Kim et al. reported the findings from the phase I study of ceritinib 
treatment (750 mg/d) in patients with anaplastic lymphoma kinase 
(ALK) + non–small-cell lung cancer (NSCLC), which served as the 
basis for the FDA approval of ceritinib in April 2014. Of the 255 
patients enrolled in the study, 246 patients with ALK+ NSCLC, 
included ALK inhibitor (ALKi) naive, and ALKi pretreated. An overall 
response rate (ORR) of 58.5% and a median progression-free survival 
(PFS) of 8.2 months were achieved in patients receiving ceritinib. A 
•	 ASCO Annual Meeting 
2014: Overall Survival 
(OS) in Patients with 
Advanced Non-Small Cell 
Lung Cancer (NSCLC) 
Harboring Common 
(Del19/L858R) Epidermal 
Growth Factor Receptor 
Mutations (EGFR mut) – 
Pooled Analysis of Two 
Large Open-Label Phase III 
Studies (LUX-Lung 3 [LL3] 
and LUX-Lung 6 [LL6]) 
Comparing Afatinib with 
Chemotherapy (CT)
receptor (EGFR) mutations (Del19/L858R), who had no 
prior treatments. Patients were randomized to afatinib 
or CT: cisplatin and pemetrexed (LUX-Lung 3 [LL3], 
n = 345); cisplatin and gemcitabine (LUX-Lung 6 
[LL6], n = 364). Prolonged PFS was previously reported 
in patients with the common EGFR mutations, receiving 
afatinib versus CT (HR = 0.47 [LL3], HR = 0.25 [LL6]). 
OS was followed up for a median of 36.5 months. The 
afatinib arm showed a significantly improved OS versus 
CT (median 27.3 versus 24.3 months; HR = 0.81; 
p = 0.037). Exclusive survival benefit was seen in those 
patients with Del19 (HR = 0.59; p < 0.001) compared 
with L858R (HR = 1.25; p = 0.160). This analysis 
demonstrated that first-line afatinib significantly 
improves OS compared with CT in patients harboring 
Del19. The author suggested that two distinct patient 
populations with Del19 and L858R should be studied 
separately in the future.
The pooled analysis of LL3 and LL6 studies aimed to show 
mature data on overall survival (OS), comparing afatinib with 
chemotherapy (CT) in patients with stage III/IV non–small-cell lung 
cancer (NSCLC) harboring the common epidermal growth factor 
•	 ASCO Annual Meeting 
2014: Efficacy and Safety 
of Crizotinib in Patients 
with Advanced  C-MET-
Amplified Non-Small Cell 
Lung Cancer (NSCLC) 
one partial response and four stable diseases whereas 
those with high c-MET amplification had one complete 
response, three partial responses and one stable disease. 
Overall objective response rates were 0% (low), 17% 
(intermediate), and 67% (high). The response lasted for 
a median of 35 weeks, with six patients still undergoing 
treatment at data cut-off. There were five disease-
related deaths. Treatment related adverse events, mostly 
grade 1, occurred in 75% of the patients. The findings 
suggested antitumor efficacy of crizotinib in patients 
with c-MET amplified non–small-cell lung cancer, 
with a tolerable and manageable safety profile. Further 
studies of crizotinib in this patient population and 
the association of c-MET amplification with clinical 
outcomes are warranted.
The results of the phase I dose escalation study of crizotinib in 
13 patients with advanced non–small-cell lung cancer harboring 
MET amplification were presented by Camidge et al. at the 
ASCO Annual Meeting 2014. c-MET amplification status was 
determined by fluorescent in situ hybridization and categorized 
into low (MET/CEP7 ratio ≥1.8 to ≤2.2; n = 1), intermediate (>2.2 
to <5; n = 6), and high (≥5; n = 6). Of the 12 patients evaluable 
for response, those with intermediate c-MET amplification had 
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•	 ISDS Provisions and Big 
Tobacco
smoke-and-mirrors-in-trade-disputes-will-harm-public-
health/) looks at the effects of Investor-State Dispute 
Settlement (ISDS) Provisions employed by global 
tobacco companies in opposition to moves such as 
Australia’s introduction of plain cigarette packaging 
as well the use of graphic health warnings by Uruguay 
and Switzerland. Dr Margaret Chan, WHO’s Director-
General, raised the problem of such provisions in a 
recent speech at the UN, pointing out that the tobacco 
companies use them to sue governments for lost profits, 
a step which is “fundamentally wrong” when it permits 
trade agreements to override public health measures. 
The article contains a link to the speech; the reference to 
these provisions occurs about 7 minutes from the start.
This month we revisit plain packaging for cigarettes and the 
international legal game of Twister that has ensued. A report in 
the East Asia Forum (http://www.eastasiaforum.org/2014/05/29/
Photo source: WHO
•	 Think Globally, Act Locally A small step was taken on World No Tobacco Day, 
May 31 2014, when the University of NSW in Sydney, 
Australia, banned smoking from all of its eight campuses, 
as reported in the Sydney Morning Herald. The ban 
includes e-cigarettes, water pipes, and vaporizers (http://
www.smh.com.au/nsw/total-smoking-ban-on-every-
unsw-campus-20140530-399rz.html). The university’s 
website provides more information at the following link, 
http://sustainability.unsw.edu.au/news/smokefree.
On the other side of the world, The Republic of 
Ireland is proposing legislation from plain cigarette 
packaging, reported by the BBC (http://www.bbc.com/
news/world-europe-27781825). Cabinet has approved 
draft laws as reported in The Irish Times, banning logos 
on cigarette packs, forbidding the term “low tar” and 
mandating graphic warnings (http://www.irishtimes.
com/news/health/ireland-leads-eu-on-plain-packaging-
of-cigarettes-1.1827268).
Photo credit: CDC | Debora Cartagena
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•	 E-Cig Update org/article/S0749-3797(13)00618-1/abstract). And 
finally, perhaps there is a flipside to the concerns about 
e-cigarettes. A study on e-cigarette use and smoking 
cessation, reported on by the BBC and Britain’s Daily 
Telegraph, has shown a higher cessation rate in users of 
e-cigarettes than those who used nicotine replacement 
therapies or no aid at all. The authors are cautious in 
their discussion of the findings, citing the potential recall 
bias, the lack of biochemical verification of abstinence 
and the heterogeneity of nicotine replacement including 
the nicotine content of e-cigarettes. The paper’s senior 
author is among the co-signatories of letter, reported by 
The Guardian (http://www.theguardian.com/world/2014/
may/29/who-suppress-control-e-cigarettes-uk-health-
tobacco) from more than 50 researchers and specialists 
to Dr Margaret Chan, calling for e-cigarettes to be 
regulated as part of “tobacco harm-reduction” strategies 
and expressing concerns about detrimental effects of a 
total ban. The letter can be viewed at http://nicotinepolicy.
net. These research findings, and the calls for e-cigarettes 
to be considered as part of the tobacco-harm reduction 
armamentarium, add to the complexity of the e-cigarette 
debate and to the importance of careful and sophisticated 
interpretation of data and their application to health care 
regulations.
In the May issue of the Journal of General Internal Medicine (http://
link.springer.com/article/10.1007/s11606-014-2889-7), a new 
study has found that e-cigarettes outdo older (and Food and Drug 
Administration-approved) nicotine inhaler devices in popularity. The 
small cross-over trial found that e-cigarettes were more acceptable 
than the inhaler, with a higher perceived benefit and a higher rating 
for “coolness”. One explanation for this perhaps comes from a study 
in Pediatrics, published online June 2 2014, looking at e-cigarette TV 
advertisements across 2011 to 2013. Reported in USA Today (http://
www.usatoday.com/story/news/nation/2014/06/02/e-cigarettes-tv-ads-
youth/9760425/), the study found that e-cigarette TV advertisement 
exposure over that time increased by 256% for 12–17 years of age 
and by 321% for 18–24 years of age. The advertisements themselves 
have all of the conventional ingredients (pretty blonde women, night 
club scenes, health, happiness, and vitality) seen in advertisements 
for anything, anywhere and were dominated by one brand, blu eCigs, 
owned by the tobacco company Lorillard. It is interesting to note 
that a ban on TV advertisements for conventional cigarettes has been 
in place in the United States since 1971. Advertising expenditure 
for e-cigarettes, in data published in the American Journal of 
Preventive Medicine increased almost three fold between 2011 and 
2012 (from $6.4 million to $18.3 million; http://www.ajpmonline.
